ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0539

Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort

Liese de Bruin1, Floris A. van Gaalen1, Manouk de Hooge2, Miranda van Lunteren1, Mary Lucy Marques3, Monique Reijnierse4, Roberta Ramonda5, Inger Jorid Berg6, Sofia Exarchou7, Robert Landewé8, Désirée Van Der Heijde1 and Sofia Ramiro9, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, 4Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 5Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy, 66Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Nepal, 7Lund University, Åkarp, Skane Lan, Sweden, 8Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, 9Leiden University Medical Center, Bunde, Netherlands

Meeting: ACR Convergence 2025

Keywords: Imaging, Magnetic resonance imaging (MRI), Outcome measures, radiography, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The assessment of structural damage progression is an important part of outcome assessment in axial SpA (axSpA). In order to test whether interventions can potentially inhibit structural damage progression, an outcome measurement instrument that is sensitive to change is essential. We aimed at comparing the sensitivity to change of different methods assessing structural lesions on conventional radiographs and on MRI of the sacroiliac joints (SIJ) and the spine in patients with early axSpA.

Methods: Patients with chronic back pain (≥3 months; ≤2 years; onset < 45 years) from the SPondyloArthritis Caught Early (SPACE) cohort received a rheumatologist’s diagnosis of axSpA or non-axSpA after two years follow-up. Only patients with an axSpA diagnosis were included in this analysis. Radiographs and MRIs of the SIJ (MRI-SIJ) and spine (MRI-spine) were obtained at baseline, 3 months, 1 and 2 years of follow-up, and scored for structural lesions (Table 1) by at least 2 and a maximum of 3 readers in two reading rounds. All patients with ≥1 score from ≥1 reader from ≥1 timepoint from ≥1 reading round were included in the analysis. To allow comparison across outcomes, the standardized rate of change was calculated using integrated multilevel generalized estimating equations while considering the individual readers and reading round. To facilitate the comparison across imaging outcomes, the relative standardized rate of change was calculated by dividing the standardized rate of change of the imaging outcome by that of an outcome chosen as the reference. Additionally, one outcome was chosen as a reference for each anatomic site for comparison of the outcomes at the site level. The imaging outcome with the highest standardized rate of change per year was chosen as reference, both overall and for each anatomic site. A sensitivity analysis was conducted in patients with all scores from ≥2 timepoints available.

Results: In total, 332 patients with axSpA (mean age 30 (SD 8) years; 53% males) were included in the main analysis, of which 295 (89%) had all scores from ≥2 timepoints. The yearly (relative) standardized rate of change of each imaging outcome is shown in Table 1. From all outcomes, MRI-SIJ total structural lesions without sclerosis had the highest standardized rate of change per year, also meaning that SIJ structural lesions were more sensitive to change than spinal lesions. From the spine outcomes, MRI total fat lesions had highest standardized rate of change. In addition, total fat lesions were highly sensitive both in the SIJ and spine (Figure 1). In contrast, outcomes with erosions or (partial) ankylosis were less sensitive to change. The sensitivity analysis showed similar findings.

Conclusion: Compared to MRI-spine and radiographs SIJ and spine, MRI-SIJ structural lesions are generally most sensitive to change. Fat lesions are most sensitive to change, especially on the MRI-SIJ. Erosions and ankylosis are less sensitive outcomes.

Supporting image 1

Supporting image 2Figure 1. Relative rate of mean change using a reference per anatomic site with total structural lesions without sclerosis set as the reference. The total of structural lesions in the MRI of the sacroiliac joints is a sum of erosions, fat lesions, (partial) ankylosis, and sclerosis. The total of structural lesions in the MRI of the spine is a sum of erosions, fat lesions, bone spurs and ankylosis. mNY, modified New York criteria; No., number; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score.


Disclosures: L. de Bruin: None; F. van Gaalen: AbbVie, 2, BMS, 2, Eli Lilly, 2, Jacobus Stichting, 5, MSD, 2, Novartis, 2, 5, Stichting ASAS, 5, Stichting vrienden van Sole Mio, 5, UCB, 5; M. de Hooge: UCB pharma, 2; M. van Lunteren: None; M. Marques: Novartis, 2, 6; M. Reijnierse: None; R. Ramonda: None; I. Berg: None; S. Exarchou: AbbVie/Abbott, 1, 5, Amgen, 1, 5, Eli Lilly, 1, 5, Janssen, 1, Novartis, 1, 5, 6, Pfizer, 5, UCB, 1, 6; R. Landewé: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, Janssen, 2, Joint Imaging BV, 12, Director, Novartis, 2, Pfizer, 2, Rheumatology Consultancy BV, 12, Director, UCB, 2; D. Van Der Heijde: AbbVie, 2, Alfasigma, 2, Annals of the Rheumatic Diseases, 12, Associate editor, ArgenX, 2, Bristol Myers Squibb, 2, Eli Lilly and Company, 2, Grey-Wolf Therapeutics, 2, Imaging Rheumatology BV, 12, Director, Janssen, 2, Journal of Rheumatology, 12, Editorial board member, Novartis, 2, Pfizer, 2, RMD Open, 12, Editoral board member, Takeda, 2, UCB, 2; S. Ramiro: AbbVie, 2, 5, Eli Lilly, 2, 5, Galapagos/Alfasigma, 2, 5, Janssen, 2, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

de Bruin L, van Gaalen F, de Hooge M, van Lunteren M, Marques M, Reijnierse M, Ramonda R, Berg I, Exarchou S, Landewé R, Van Der Heijde D, Ramiro S. Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/which-instrument-measuring-structural-damage-progression-in-axial-spa-is-most-sensitive-to-change-analyses-from-the-spondyloarthritis-caught-early-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/which-instrument-measuring-structural-damage-progression-in-axial-spa-is-most-sensitive-to-change-analyses-from-the-spondyloarthritis-caught-early-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology